{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:35:51Z","timestamp":1785544551659,"version":"3.56.0"},"reference-count":89,"publisher":"Archives of Pathology and Laboratory Medicine","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,6,1]]},"abstract":"<jats:sec>\n                    <jats:title>Context.\u2014<\/jats:title>\n                    <jats:p>Chimeric antigen receptor T-cell (CAR-T) technology has shown great promise in both clinical and preclinical models in mediating potent and specific antitumor activity. With the advent of US Food and Drug Administration\u2013approved CAR-T therapies for B-cell lymphoblastic leukemia and B-cell non-Hodgkin lymphomas, CAR-T therapy is poised to become part of mainstream clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective.\u2014<\/jats:title>\n                    <jats:p>To educate pathologists on CAR-T and chimeric antigen receptor\u2013derived cellular therapy, provide a better understanding of their role in this process, explain important regulatory aspects of CAR-T therapy, and advocate for pathologist involvement in the delivery and monitoring of chimeric antigen receptor\u2013based treatments. Much of the focus of this article addresses US Food and Drug Administration\u2013approved therapies; however, more general issues and future perspectives are considered for therapies in development.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design.\u2014<\/jats:title>\n                    <jats:p>A CAR-T workgroup, facilitated by the College of American Pathologists Personalized Health Care Committee and consisting of pathologists of various backgrounds, was convened to develop a summary guidance paper for the College of American Pathologists Council on Scientific Affairs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.\u2014<\/jats:title>\n                    <jats:p>The workgroup identified gaps in pathologists' knowledge of CAR-T therapy, including uncertainty in the role of the clinical laboratory in supporting CAR-T therapy. The workgroup considered these issues and summarized the findings to assist pathologists to become stakeholders in CAR-T therapy administration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.\u2014<\/jats:title>\n                    <jats:p>This manuscript serves to both educate pathologists on CAR-T therapy and serve as a point of initial discussions in areas of CAR-T science, clinical therapy, and regulatory issues as CAR-T therapies continue to be introduced into clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5858\/arpa.2019-0632-cp","type":"journal-article","created":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T12:50:01Z","timestamp":1606308601000},"page":"704-716","source":"Crossref","is-referenced-by-count":4,"title":["A Primer on Chimeric Antigen Receptor T-cell Therapy: What Does It Mean for Pathologists?"],"prefix":"10.5858","volume":"145","author":[{"given":"Allison M.","family":"Cushman-Vokoun","sequence":"first","affiliation":[{"name":"From the Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha (Cushman-Vokoun)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl V.","family":"Voelkerding","sequence":"additional","affiliation":[{"name":"The Department of Pathology, University of Utah School of Medicine and ARUP Laboratories, Salt Lake City (Voelkerding)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark K.","family":"Fung","sequence":"additional","affiliation":[{"name":"Pathology and Laboratory Medicine, University of Vermont Medical Center, Burlington (Fung)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan A.","family":"Nowak","sequence":"additional","affiliation":[{"name":"The Department of Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York (Nowak)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Thorson","sequence":"additional","affiliation":[{"name":"The Department of Pathology, University of California San Diego, La Jolla (Thorson)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena L.","family":"Duncan","sequence":"additional","affiliation":[{"name":"Policy and Advocacy, College of American Pathologists, Washington, DC (Duncan)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Kalicanin","sequence":"additional","affiliation":[{"name":"Proficiency Testing, College of American Pathologists, Northfield, Illinois (Kalicanin)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew W.","family":"Anderson","sequence":"additional","affiliation":[{"name":"Diagnostic Laboratories, Versiti Wisconsin, Milwaukee (Anderson)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Yohe","sequence":"additional","affiliation":[{"name":"The Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis (Yohe)"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3906","published-online":{"date-parts":[[2020,11,25]]},"reference":[{"key":"2021052618104167200_i1543-2165-145-6-704-b01","doi-asserted-by":"crossref","unstructured":"Zych AO, Bajor M, Zagozdzon R. Application of genome editing techniques in immunology. Arch Immunol Ther Exp (Warsz). 2018; 66(4): 289\u2013 298. doi:10.1007\/s00005-018-0504-z","DOI":"10.1007\/s00005-018-0504-z"},{"key":"2021052618104167200_i1543-2165-145-6-704-b02","doi-asserted-by":"crossref","unstructured":"Sentman CL. Challenges of creating effective chimeric antigen receptors for cancer therapy. Immunotherapy. 2013; 5(8): 783\u2013 785. doi:10.2217\/imt.13.71","DOI":"10.2217\/imt.13.71"},{"key":"2021052618104167200_i1543-2165-145-6-704-b03","doi-asserted-by":"crossref","unstructured":"Jackson HJ, Rafiq S, Brentjens RJ. Driving CAR T-cells forward. Nat Rev Clin Oncol. 2016; 13(6): 370\u2013 383. doi:10.1038\/nrclinonc.2016.36","DOI":"10.1038\/nrclinonc.2016.36"},{"key":"2021052618104167200_i1543-2165-145-6-704-b04","doi-asserted-by":"crossref","unstructured":"Mehta RS, Rezvani K. Chimeric antigen receptor expressing natural killer cells for the immunotherapy of cancer. Front Immunol. 2018; 9: 283. doi:10.3389\/fimmu.2018.00283","DOI":"10.3389\/fimmu.2018.00283"},{"key":"2021052618104167200_i1543-2165-145-6-704-b05","doi-asserted-by":"crossref","unstructured":"Eshhar Z. From the mouse cage to human therapy: a personal perspective of the emergence of T-bodies\/chimeric antigen receptor T cells. Hum Gene Ther. 2014; 25(9): 773\u2013 778. doi:10.1089\/hum.2014.2532","DOI":"10.1089\/hum.2014.2532"},{"key":"2021052618104167200_i1543-2165-145-6-704-b06","doi-asserted-by":"crossref","unstructured":"Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci U S A. 1989; 86(24): 10024\u2013 10028.","DOI":"10.1073\/pnas.86.24.10024"},{"key":"2021052618104167200_i1543-2165-145-6-704-b07","doi-asserted-by":"crossref","unstructured":"Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A. 1993; 90(2): 720\u2013 724. doi:10.1073\/pnas.90.2.720","DOI":"10.1073\/pnas.90.2.720"},{"key":"2021052618104167200_i1543-2165-145-6-704-b08","doi-asserted-by":"crossref","unstructured":"Finney HM, Lawson ADG, Bebbington CR, Weir ANC. Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J Immunol. 1998; 161(6): 2791\u2013 2797.","DOI":"10.4049\/jimmunol.161.6.2791"},{"key":"2021052618104167200_i1543-2165-145-6-704-b09","doi-asserted-by":"crossref","unstructured":"Tammana S, Huang X, Wong M, et al. 4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies. Hum Gene Ther. 2010; 21(1): 75\u2013 86. doi:10.1089\/hum.2009.122","DOI":"10.1089\/hum.2009.122"},{"key":"2021052618104167200_i1543-2165-145-6-704-b10","doi-asserted-by":"crossref","unstructured":"June CH, O'Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018; 359(6382): 1361\u2013 1365. doi:10.1126\/science.aar6711","DOI":"10.1126\/science.aar6711"},{"key":"2021052618104167200_i1543-2165-145-6-704-b11","doi-asserted-by":"crossref","unstructured":"Weinkove R, George P, Dasyam N, McLellan AD. Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations. Clin Transl Immunol.2019; 8(5). doi:10.1002\/cti2.1049","DOI":"10.1002\/cti2.1049"},{"key":"2021052618104167200_i1543-2165-145-6-704-b12","doi-asserted-by":"crossref","unstructured":"Lipowska-Bhalla G, Gilham DE, Hawkins RE, Rothwell DG. Targeted immunotherapy of cancer with CAR T cells: achievements and challenges. Cancer Immunol Immunother. 2012; 61(7): 953\u2013 962. doi:10.1007\/s00262-012-1254-0","DOI":"10.1007\/s00262-012-1254-0"},{"key":"2021052618104167200_i1543-2165-145-6-704-b13","doi-asserted-by":"crossref","unstructured":"Chmielewski M, Abken H. CAR T cells transform to trucks: chimeric antigen receptor\u2013redirected T cells engineered to deliver inducible IL-12 modulate the tumour stroma to combat cancer. Cancer Immunol Immunother. 2012; 61(8): 1269\u2013 1277. doi:10.1007\/s00262-012-1202-z","DOI":"10.1007\/s00262-012-1202-z"},{"key":"2021052618104167200_i1543-2165-145-6-704-b14","doi-asserted-by":"crossref","unstructured":"Yu S, Yi M, Qin S, Wu K. Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity. Mol Cancer. 2019; 18(1): 125. doi:10.1186\/s12943-019-1057-4","DOI":"10.1186\/s12943-019-1057-4"},{"key":"2021052618104167200_i1543-2165-145-6-704-b15","doi-asserted-by":"crossref","unstructured":"Guedan S, Alemany R. CAR-T cells and oncolytic viruses: joining forces to overcome the solid tumor challenge. Front Immunol.2018; 9. doi:10.3389\/fimmu.2018.02460","DOI":"10.3389\/fimmu.2018.02460"},{"key":"2021052618104167200_i1543-2165-145-6-704-b16","doi-asserted-by":"crossref","unstructured":"Benmebarek M-R, Karches CH, Cadilha BL, Lesch S, Endres S, Kobold S. Killing mechanisms of chimeric antigen receptor (CAR) T cells. Int J Mol Sci.2019; 20(6). doi:10.3390\/ijms20061283","DOI":"10.3390\/ijms20061283"},{"key":"2021052618104167200_i1543-2165-145-6-704-b17","doi-asserted-by":"crossref","unstructured":"Till BG, Jensen MC, Wang J, et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood. 2008; 112(6): 2261\u2013 2271. doi:10.1182\/blood-2007-12-128843","DOI":"10.1182\/blood-2007-12-128843"},{"key":"2021052618104167200_i1543-2165-145-6-704-b18","doi-asserted-by":"crossref","unstructured":"Till BG, Jensen MC, Wang J, et al. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood. 2012; 119(17): 3940\u2013 3950. doi:10.1182\/blood-2011-10-387969","DOI":"10.1182\/blood-2011-10-387969"},{"key":"2021052618104167200_i1543-2165-145-6-704-b19","doi-asserted-by":"crossref","unstructured":"Zah E, Lin M-Y, Silva-Benedict A, Jensen MC, Chen YY. T cells expressing CD19\/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells. Cancer Immunol Res. 2016; 4(6): 498\u2013 508. doi:10.1158\/2326-6066.CIR-15-0231","DOI":"10.1158\/2326-6066.CIR-15-0231"},{"key":"2021052618104167200_i1543-2165-145-6-704-b20","unstructured":"Modified immune cells (CD19\/CD20 CAR-T cells) in treating patients with recurrent or refractory B-Cell lymphoma or chronic lymphocytic leukemia. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04007029. AccessedMarch6,2020."},{"key":"2021052618104167200_i1543-2165-145-6-704-b21","doi-asserted-by":"crossref","unstructured":"Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor\u2013modified T cells for acute lymphoid leukemia. N Engl J Med. 2013; 368(16): 1509\u2013 1518. doi:10.1056\/NEJMoa1215134","DOI":"10.1056\/NEJMoa1215134"},{"key":"2021052618104167200_i1543-2165-145-6-704-b22","doi-asserted-by":"crossref","unstructured":"Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014; 371(16): 1507\u2013 1517. doi:10.1056\/NEJMoa1407222","DOI":"10.1056\/NEJMoa1407222"},{"key":"2021052618104167200_i1543-2165-145-6-704-b23","doi-asserted-by":"crossref","unstructured":"Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med.2014; 6(224): 224ra25.doi:10.1126\/scitranslmed.3008226","DOI":"10.1126\/scitranslmed.3008226"},{"key":"2021052618104167200_i1543-2165-145-6-704-b24","doi-asserted-by":"crossref","unstructured":"Park JH, Rivi\u00e8re I, Gonen M, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018; 378(5): 449\u2013 459. doi:10.1056\/NEJMoa1709919","DOI":"10.1056\/NEJMoa1709919"},{"key":"2021052618104167200_i1543-2165-145-6-704-b25","doi-asserted-by":"crossref","unstructured":"Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015; 385(9967): 517\u2013 528. doi:10.1016\/S0140-6736(14)61403-3","DOI":"10.1016\/S0140-6736(14)61403-3"},{"key":"2021052618104167200_i1543-2165-145-6-704-b26","doi-asserted-by":"crossref","unstructured":"Schuster SJ, Svoboda J, Chong EA, et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med. 2017; 377(26): 2545\u2013 2554. doi:10.1056\/NEJMoa1708566","DOI":"10.1056\/NEJMoa1708566"},{"key":"2021052618104167200_i1543-2165-145-6-704-b27","doi-asserted-by":"crossref","unstructured":"Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-Cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017; 377(26): 2531\u2013 2544. doi:10.1056\/NEJMoa1707447","DOI":"10.1056\/NEJMoa1707447"},{"key":"2021052618104167200_i1543-2165-145-6-704-b28","unstructured":"Kymriah (tisagenlecleucel). US Food and Drug Administration Web site. http:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/kymriah-tisagenlecleucel. Published online April 5, 2019. AccessedJuly3,2019."},{"key":"2021052618104167200_i1543-2165-145-6-704-b29","unstructured":"Yescarta (axicabtagene ciloleucel). US Food and Drug Administration Web site. http:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/yescarta-axicabtagene-ciloleucel. Published April 24, 2019. AccessedJuly3,2019."},{"key":"2021052618104167200_i1543-2165-145-6-704-b30","doi-asserted-by":"crossref","unstructured":"Doan A, Pulsipher MA. Hypogammaglobulinemia due to CAR T-cell therapy. Pediatr Blood Cancer. 2018; 65(4). doi:10.1002\/pbc.26914","DOI":"10.1002\/pbc.26914"},{"key":"2021052618104167200_i1543-2165-145-6-704-b31","doi-asserted-by":"crossref","unstructured":"Bhoj VG, Arhontoulis D, Wertheim G, et al. Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy. Blood. 2016; 128(3): 360\u2013 370. doi:10.1182\/blood-2016-01-694356","DOI":"10.1182\/blood-2016-01-694356"},{"key":"2021052618104167200_i1543-2165-145-6-704-b32","doi-asserted-by":"crossref","unstructured":"Shimabukuro-Vornhagen A, G\u00f6del P, Subklewe M, et al. Cytokine release syndrome. J Immunother Cancer. 2018; 6(1): 56. doi:10.1186\/s40425-018-0343-9","DOI":"10.1186\/s40425-018-0343-9"},{"key":"2021052618104167200_i1543-2165-145-6-704-b33","doi-asserted-by":"crossref","unstructured":"Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019; 25(4): 625\u2013 638. doi:10.1016\/j.bbmt.2018.12.758","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"2021052618104167200_i1543-2165-145-6-704-b34","doi-asserted-by":"crossref","unstructured":"Ahmed O. CAR-T\u2013cell neurotoxicity: hope is on the horizon. Blood. 2019; 133(20): 2114\u2013 2116. doi:10.1182\/blood-2019-03-900985","DOI":"10.1182\/blood-2019-03-900985"},{"key":"2021052618104167200_i1543-2165-145-6-704-b35","doi-asserted-by":"crossref","unstructured":"Neelapu SS. Managing the toxicities of CAR T-cell therapy. Hematol Oncol. 2019; 37(suppl 1): 48\u2013 52. doi:10.1002\/hon.2595","DOI":"10.1002\/hon.2595"},{"key":"2021052618104167200_i1543-2165-145-6-704-b36","doi-asserted-by":"crossref","unstructured":"Liu S, Deng B, Yin Z, et al. Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemia. Blood Cancer J.2020; 10(2). doi:10.1038\/s41408-020-0280-y","DOI":"10.1038\/s41408-020-0280-y"},{"key":"2021052618104167200_i1543-2165-145-6-704-b37","doi-asserted-by":"crossref","unstructured":"Gust J, Hay KA, Hanafi L-A, et al. Endothelial activation and blood\u2013brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 2017; 7(12): 1404\u2013 1419. doi:10.1158\/2159-8290.CD-17-0698","DOI":"10.1158\/2159-8290.CD-17-0698"},{"key":"2021052618104167200_i1543-2165-145-6-704-b38","doi-asserted-by":"crossref","unstructured":"Santomasso BD, Park JH, Salloum D, et al. Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov. 2018; 8(8): 958\u2013 971. doi:10.1158\/2159-8290.CD-17-1319","DOI":"10.1158\/2159-8290.CD-17-1319"},{"key":"2021052618104167200_i1543-2165-145-6-704-b39","doi-asserted-by":"crossref","unstructured":"Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia. N Engl J Med. 2018; 378(5): 439\u2013 448. doi:10.1056\/NEJMoa1709866","DOI":"10.1056\/NEJMoa1709866"},{"key":"2021052618104167200_i1543-2165-145-6-704-b40","doi-asserted-by":"crossref","unstructured":"Shah NN, Fry TJ. Mechanisms of resistance to CAR T cell therapy. Nat Rev Clin Oncol. 2019; 16(6): 372\u2013 385. doi:10.1038\/s41571-019-0184-6","DOI":"10.1038\/s41571-019-0184-6"},{"key":"2021052618104167200_i1543-2165-145-6-704-b41","doi-asserted-by":"crossref","unstructured":"Wang H, Du X, Chen W-H, et al. Establishment of a quantitative polymerase chain reaction assay for monitoring chimeric antigen receptor T cells in peripheral blood. Transplant Proc. 2018; 50(1): 104\u2013 109. doi:10.1016\/j.transproceed.2017.11.028","DOI":"10.1016\/j.transproceed.2017.11.028"},{"key":"2021052618104167200_i1543-2165-145-6-704-b42","doi-asserted-by":"crossref","unstructured":"Jozwik A, Dunlop A, Sanchez K, Benjamin R. Monitoring allogeneic CAR-T cells using flow cytometry. Methods Mol Biol. 2020; 2097: 293\u2013 308. doi:10.1007\/978-1-0716-0203-4_19","DOI":"10.1007\/978-1-0716-0203-4_19"},{"key":"2021052618104167200_i1543-2165-145-6-704-b43","doi-asserted-by":"crossref","unstructured":"de Azevedo JTC, Mizukami A, Mo\u00e7o PD, Malmegrim KCR. Immunophenotypic analysis of CAR-T cells. Methods Mol Biol. 2020; 2086: 195\u2013 201. doi:10.1007\/978-1-0716-0146-4_14","DOI":"10.1007\/978-1-0716-0146-4_14"},{"key":"2021052618104167200_i1543-2165-145-6-704-b44","doi-asserted-by":"crossref","unstructured":"Patel S, Burga RA, Powell AB, et al. Beyond CAR T cells: other cell-based immunotherapeutic strategies against cancer. Front Oncol. 2019; 9: 196. doi:10.3389\/fonc.2019.00196","DOI":"10.3389\/fonc.2019.00196"},{"key":"2021052618104167200_i1543-2165-145-6-704-b45","doi-asserted-by":"crossref","unstructured":"Yao J, Ly D, Dervovic D, et al. Human double negative T cells target lung cancer via ligand-dependent mechanisms that can be enhanced by IL-15. J Immunother Cancer. 2019; 7(1): 17. doi:10.1186\/s40425-019-0507-2","DOI":"10.1186\/s40425-019-0507-2"},{"key":"2021052618104167200_i1543-2165-145-6-704-b46","doi-asserted-by":"crossref","unstructured":"Li C, Mei H, Hu Y. Applications and explorations of CRISPR\/Cas9 in CAR T-cell therapy [published online January 17, 2020]. Brief Funct Genomics. doi:10.1093\/bfgp\/elz042","DOI":"10.1093\/bfgp\/elz042"},{"key":"2021052618104167200_i1543-2165-145-6-704-b47","doi-asserted-by":"crossref","unstructured":"Graham C, Jozwik A, Pepper A, Benjamin R. Allogeneic CAR-T cells: more than ease of access? Cells . 2018; 7(10): 155. doi:10.3390\/cells7100155","DOI":"10.3390\/cells7100155"},{"key":"2021052618104167200_i1543-2165-145-6-704-b48","unstructured":"Lu XV. Summary basis for regulatory action. https:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/CellularGeneTherapyProducts\/ApprovedProducts\/UCM577221.pdf. Accessed March 18,2019."},{"key":"2021052618104167200_i1543-2165-145-6-704-b49","unstructured":"Havert M. Summary basis for regulatory action. https:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/CellularGeneTherapyProducts\/ApprovedProducts\/UCM584335.pdf. Accessed March 18,2019."},{"key":"2021052618104167200_i1543-2165-145-6-704-b50","unstructured":"Statement from FDA Commissioner Scott Gottlieb, MD, and Peter Marks, MD, PhD, Director of the Center for Biologics Evaluation and Research on new policies to advance development of safe and effective cell and gene therapies. https:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm629493.htm. Published January 15,2019. Accessed March 25,2019."},{"key":"2021052618104167200_i1543-2165-145-6-704-b51","unstructured":"Foundation for the Accreditation of Cellular Therapy. FACT Standards for Immune Effector Cells. 1st ed. Version 1.1.https:\/\/www.factweb.org\/forms\/store\/ProductFormPublic\/first-edition-v1-1-fact-standards-for-immune-effector-cells-free-download. Published March 18, 2019. Accessed March 18,2019."},{"key":"2021052618104167200_i1543-2165-145-6-704-b52","unstructured":"Long term follow-up after administration of human gene therapy products; draft guidance for industry; availability. https:\/\/www.federalregister.gov\/documents\/2018\/07\/12\/2018-14867\/long-term-follow-up-after-administration-of-human-gene-therapy-products-draft-guidance-for-industry. Published July 12,2018. AccessedMarch18,2019."},{"key":"2021052618104167200_i1543-2165-145-6-704-b53","doi-asserted-by":"crossref","unstructured":"Laetsch TW, Maude SL, Milone MC, et al. False-positive results with select HIV-1 NAT methods following lentivirus-based tisagenlecleucel therapy. Blood. 2018; 131(23): 2596\u2013 2598. doi:10.1182\/blood-2017-12-822940","DOI":"10.1182\/blood-2017-12-822940"},{"key":"2021052618104167200_i1543-2165-145-6-704-b54","unstructured":"Brin K, Synovec M, Barney L, et al. Category III Codes. In: Brin K, Synovec M, Barney L, et al, eds. Current Procedural Terminology (CPT). 4th ed. American Medical Association; 2019: 789."},{"key":"2021052618104167200_i1543-2165-145-6-704-b55","unstructured":"CMS-1694-F and CMS-1694-CN2. Centers for Medicare & Medicaid Services. https:\/\/www.cms.gov\/Medicare\/Medicare-Fee-for-Service-Payment\/AcuteInpatientPPS\/FY2019-IPPS-Final-Rule-Home-Page-Items\/FY2019-IPPS-Final-Rule-Regulations.html. AccessedMarch21,2019."},{"key":"2021052618104167200_i1543-2165-145-6-704-b56","unstructured":"Ahle S. Are CAR T-cell therapies worth the costs? ASH Clin News. https:\/\/www.ashclinicalnews.org\/spotlight\/drawing-first-blood\/car-t-cell-therapies-worth-costs\/. Published February 1, 2020. Accessed March 31,2020."},{"key":"2021052618104167200_i1543-2165-145-6-704-b57","doi-asserted-by":"crossref","unstructured":"Roth JA, Sullivan SD, Lin VW, et al. Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States. J Med Econ. 2018; 21(12): 1238\u2013 1245. doi:10.1080\/13696998.2018.1529674","DOI":"10.1080\/13696998.2018.1529674"},{"key":"2021052618104167200_i1543-2165-145-6-704-b58","doi-asserted-by":"crossref","unstructured":"Whittington MD, McQueen RB, Ollendorf DA, et al. Long-term survival and cost-effectiveness associated with axicabtagene ciloleucel vs chemotherapy for treatment of B-cell lymphoma. JAMA Netw Open. 2019; 2(2): e190035. doi:10.1001\/jamanetworkopen.2019.0035","DOI":"10.1001\/jamanetworkopen.2019.0035"},{"key":"2021052618104167200_i1543-2165-145-6-704-b59","doi-asserted-by":"crossref","unstructured":"Whittington MD, McQueen RB, Ollendorf DA, et al. Long-term survival and value of chimeric antigen receptor T-cell therapy for pediatric patients with relapsed or refractory leukemia. JAMA Pediatr. 2018; 172(12): 1161\u2013 1168. doi:10.1001\/jamapediatrics.2018.2530","DOI":"10.1001\/jamapediatrics.2018.2530"},{"key":"2021052618104167200_i1543-2165-145-6-704-b60","doi-asserted-by":"crossref","unstructured":"Porter DL, Hwang W-T, Frey NV, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med.2015; 7(303): 303ra139.doi:10.1126\/scitranslmed.aac5415","DOI":"10.1126\/scitranslmed.aac5415"},{"key":"2021052618104167200_i1543-2165-145-6-704-b61","doi-asserted-by":"crossref","unstructured":"Fraietta JA, Lacey SF, Orlando EJ, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med. 2018; 24(5): 563\u2013 571. doi:10.1038\/s41591-018-0010-1","DOI":"10.1038\/s41591-018-0010-1"},{"key":"2021052618104167200_i1543-2165-145-6-704-b62","doi-asserted-by":"crossref","unstructured":"Garfall AL, Stadtmauer EA, Hwang W-T, et al. Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI Insight. 2018; 3(8). doi:10.1172\/jci.insight.120505","DOI":"10.1172\/jci.insight.120505"},{"key":"2021052618104167200_i1543-2165-145-6-704-b63","doi-asserted-by":"crossref","unstructured":"Brudno JN, Maric I, Hartman SD, et al. T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma. J Clin Oncol. 2018; 36(22): 2267\u2013 2280. doi:10.1200\/JCO.2018.77.8084","DOI":"10.1200\/JCO.2018.77.8084"},{"key":"2021052618104167200_i1543-2165-145-6-704-b64","doi-asserted-by":"crossref","unstructured":"Chen L, Mao H, Zhang J, et al. Targeting FLT3 by chimeric antigen receptor T cells for the treatment of acute myeloid leukemia. Leukemia. 2017; 31(8): 1830\u2013 1834. doi:10.1038\/leu.2017.147","DOI":"10.1038\/leu.2017.147"},{"key":"2021052618104167200_i1543-2165-145-6-704-b65","doi-asserted-by":"crossref","unstructured":"Jetani H, Garcia-Cadenas I, Nerreter T, et al. CAR T-cells targeting FLT3 have potent activity against FLT3(\u2212)ITD(+) AML and act synergistically with the FLT3-inhibitor crenolanib. Leukemia. 2018; 32(5): 1168\u2013 1179. doi:10.1038\/s41375-018-0009-0","DOI":"10.1038\/s41375-018-0009-0"},{"key":"2021052618104167200_i1543-2165-145-6-704-b66","doi-asserted-by":"crossref","unstructured":"D'Aloia MM, Zizzari IG, Sacchetti B, Pierelli L, Alimandi M. CAR-T cells: the long and winding road to solid tumors. Cell Death Dis. 2018; 9(3): 282. doi:10.1038\/s41419-018-0278-6","DOI":"10.1038\/s41419-018-0278-6"},{"key":"2021052618104167200_i1543-2165-145-6-704-b67","doi-asserted-by":"crossref","unstructured":"Zhu F, Shah NN, Xu H, et al. CAR-T cell production using the Clinimacs\u00ae Prodigy system. Blood. 2016; 128(22): 5724\u2013 5724.","DOI":"10.1182\/blood.V128.22.5724.5724"},{"key":"2021052618104167200_i1543-2165-145-6-704-b68","doi-asserted-by":"crossref","unstructured":"Zhu F, Shah N, Xu H, et al. Closed-system manufacturing of CD19 and dual-targeted CD20\/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center. Cytotherapy. 2018; 20(3): 394\u2013 406. doi:10.1016\/j.jcyt.2017.09.005","DOI":"10.1016\/j.jcyt.2017.09.005"},{"key":"2021052618104167200_i1543-2165-145-6-704-b69","doi-asserted-by":"crossref","unstructured":"The quest for off-the-shelf CAR T cells. Cancer Discov. 2018; 8(7): 787\u2013 788. doi:10.1158\/2159-8290.CD-ND2018-005","DOI":"10.1158\/2159-8290.CD-ND2018-005"},{"key":"2021052618104167200_i1543-2165-145-6-704-b70","doi-asserted-by":"crossref","unstructured":"Liu J, Zhong JF, Zhang X, Zhang C. Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies. J Hematol Oncol. 2017; 10(1): 35. doi:10.1186\/s13045-017-0405-3","DOI":"10.1186\/s13045-017-0405-3"},{"key":"2021052618104167200_i1543-2165-145-6-704-b71","unstructured":"DiGrande S. FDA accepts first allogeneic CAR T-cell therapy trial. AJMC Web site. https:\/\/www.ajmc.com\/newsroom\/fda-accepts-first-allogeneic-car-tcell-therapy-trial. Published August 4, 2018. Accessed March 21,2019."},{"key":"2021052618104167200_i1543-2165-145-6-704-b72","unstructured":"alloSHRINK\u2014standard chemotherapy regimen and immunotherapy with allogeneic NKG2D-based CYAD-101 chimeric antigen receptor T-cells. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03692429. AccessedMarch25,2019."},{"key":"2021052618104167200_i1543-2165-145-6-704-b73","doi-asserted-by":"crossref","unstructured":"Zhang C, Liu J, Zhong JF, Zhang X. Engineering CAR-T cells. Biomark Res. 2017; 5: 22. doi:10.1186\/s40364-017-0102-y","DOI":"10.1186\/s40364-017-0102-y"},{"key":"2021052618104167200_i1543-2165-145-6-704-b74","doi-asserted-by":"crossref","unstructured":"Chmielewski M, Abken H. TRUCKs: the fourth generation of CARs. Expert Opin Biol Ther. 2015; 15(8): 1145\u2013 1154. doi:10.1517\/14712598.2015.1046430","DOI":"10.1517\/14712598.2015.1046430"},{"key":"2021052618104167200_i1543-2165-145-6-704-b75","doi-asserted-by":"crossref","unstructured":"Elahi R, Khosh E, Tahmasebi S, Esmaeilzadeh A. Immune cell hacking: challenges and clinical approaches to create smarter generations of chimeric antigen receptor T cells. Front Immunol.2018; 9. doi:10.3389\/fimmu.2018.01717","DOI":"10.3389\/fimmu.2018.01717"},{"key":"2021052618104167200_i1543-2165-145-6-704-b76","doi-asserted-by":"crossref","unstructured":"Priceman SJ, Tilakawardane D, Jeang B, et al. regional delivery of chimeric antigen receptor\u2013engineered T cells effectively targets HER2+ breast cancer metastasis to the brain. Clin Cancer Res. 2018; 24(1): 95\u2013 105. doi:10.1158\/1078-0432.CCR-17-2041","DOI":"10.1158\/1078-0432.CCR-17-2041"},{"key":"2021052618104167200_i1543-2165-145-6-704-b77","doi-asserted-by":"crossref","unstructured":"Lamers CHJ, Klaver Y, Gratama JW, Sleijfer S, Debets R. Treatment of metastatic renal cell carcinoma (mRCC) with CAIX CAR-engineered. Biochem Soc Trans. 2016; 44(3): 951\u2013 959. doi:10.1042\/BST20160037","DOI":"10.1042\/BST20160037"},{"key":"2021052618104167200_i1543-2165-145-6-704-b78","doi-asserted-by":"crossref","unstructured":"Li H, Huang Y, Jiang D-Q, et al. Antitumor activity of EGFR-specific CAR T cells against non-small-cell lung cancer cells in vitro and in mice. Cell Death Dis. 2018; 9(2): 177. doi:10.1038\/s41419-017-0238-6","DOI":"10.1038\/s41419-017-0238-6"},{"key":"2021052618104167200_i1543-2165-145-6-704-b79","doi-asserted-by":"crossref","unstructured":"Brown CE, Alizadeh D, Starr R, et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N Engl J Med. 2016; 375(26): 2561\u2013 2569. doi:10.1056\/NEJMoa1610497","DOI":"10.1056\/NEJMoa1610497"},{"key":"2021052618104167200_i1543-2165-145-6-704-b80","doi-asserted-by":"crossref","unstructured":"O'Rourke DM, Nasrallah MP, Desai A, et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med.2017; 9(399): eaaa0984.doi:10.1126\/scitranslmed.aaa0984","DOI":"10.1126\/scitranslmed.aaa0984"},{"key":"2021052618104167200_i1543-2165-145-6-704-b81","doi-asserted-by":"crossref","unstructured":"Sahin A, Sanchez C, Bullain S, Waterman P, Weissleder R, Carter BS. Development of third generation anti-EGFRvIII chimeric T cells and EGFRvIII-expressing artificial antigen presenting cells for adoptive cell therapy for glioma. PLoS One. 2018; 13(7): e0199414. doi:10.1371\/journal.pone.0199414","DOI":"10.1371\/journal.pone.0199414"},{"key":"2021052618104167200_i1543-2165-145-6-704-b82","doi-asserted-by":"crossref","unstructured":"Ren P-P, Li M, Li T-L, Han S-Y. Anti-EGFRvIII chimeric antigen receptor-modified T cells for adoptive cell therapy of glioblastoma. Curr Pharm Des. 2017; 23(14): 2113\u2013 2116. doi:10.2174\/1381612823666170316125402","DOI":"10.2174\/1381612823666170316125402"},{"key":"2021052618104167200_i1543-2165-145-6-704-b83","doi-asserted-by":"crossref","unstructured":"Chekmasova AA, Rao TD, Nikhamin Y, et al. successful eradication of established peritoneal ovarian tumors in SCID-beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen. Clin Cancer Res. 2010; 16(14): 3594\u2013 3606. doi:10.1158\/1078-0432.CCR-10-0192","DOI":"10.1158\/1078-0432.CCR-10-0192"},{"key":"2021052618104167200_i1543-2165-145-6-704-b84","doi-asserted-by":"crossref","unstructured":"Koneru M, Purdon TJ, Spriggs D, Koneru S, Brentjens RJ. IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo. Oncoimmunology. 2015; 4(3): e994446. doi:10.4161\/2162402X.2014.994446","DOI":"10.4161\/2162402X.2014.994446"},{"key":"2021052618104167200_i1543-2165-145-6-704-b85","doi-asserted-by":"crossref","unstructured":"Zhang C, Wang Z, Yang Z, et al. Phase I escalating-dose trial of CAR-T therapy targeting CEA+ metastatic colorectal cancers. Mol Ther. 2017; 25(5): 1248\u2013 1258. doi:10.1016\/j.ymthe.2017.03.010","DOI":"10.1016\/j.ymthe.2017.03.010"},{"key":"2021052618104167200_i1543-2165-145-6-704-b86","doi-asserted-by":"crossref","unstructured":"Wang L, Ma N, Okamoto S, et al. Efficient tumor regression by adoptively transferred CEA-specific CAR-T cells associated with symptoms of mild cytokine release syndrome. Oncoimmunology. 2016; 5(9): e1211218. doi:10.1080\/2162402X.2016.1211218","DOI":"10.1080\/2162402X.2016.1211218"},{"key":"2021052618104167200_i1543-2165-145-6-704-b87","doi-asserted-by":"crossref","unstructured":"Junghans RP, Ma Q, Rathore R, et al. Phase I trial of anti-PSMA designer CAR-T cells in prostate cancer: possible role for interacting interleukin 2-T Cell pharmacodynamics as a determinant of clinical response. Prostate. 2016; 76(14): 1257\u2013 1270. doi:10.1002\/pros.23214","DOI":"10.1002\/pros.23214"},{"key":"2021052618104167200_i1543-2165-145-6-704-b88","doi-asserted-by":"crossref","unstructured":"Zuccolotto G, Fracasso G, Merlo A, et al. PSMA-specific CAR-engineered T cells eradicate disseminated prostate cancer in preclinical models. PLoS One. 2014; 9(10): e109427. doi:10.1371\/journal.pone.0109427","DOI":"10.1371\/journal.pone.0109427"},{"key":"2021052618104167200_i1543-2165-145-6-704-b89","unstructured":"89. Centers for Medicare & Medicaid Services. Fiscal year (FY) 2020 Medicare Hospital Inpatient Prospective Payment System (IPPS) and Long Term Acute Care Hospital (LTCH) Prospective Payment System Proposed Rule and Request for Information. https:\/\/www.cms.gov\/newsroom\/fact-sheets\/fiscal-year-fy-2020-medicare-hospital-inpatient-prospective-payment-system-ipps-and-long-term-acute. Published April 23, 2019. Accessed October 1, 2020."}],"container-title":["Archives of Pathology &amp; Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/aplm\/article-pdf\/145\/6\/704\/2835568\/i1543-2165-145-6-704.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/aplm\/article-pdf\/145\/6\/704\/2835568\/i1543-2165-145-6-704.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T19:41:34Z","timestamp":1764790894000},"score":1,"resource":{"primary":{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/145\/6\/article-p704.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,25]]},"references-count":89,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,11,25]]},"published-print":{"date-parts":[[2021,6,1]]}},"URL":"https:\/\/doi.org\/10.5858\/arpa.2019-0632-cp","relation":{},"ISSN":["1543-2165","0003-9985"],"issn-type":[{"value":"1543-2165","type":"electronic"},{"value":"0003-9985","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11,25]]}}}